期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

紫杉醇对兔血管内皮和平滑肌细胞增生影响的差异及意义(英文) 被引量：1

Different growth response of rabbit's vascular endothelial and smooth muscle cells to Paclitaxel
暂未订购
导出
摘要 目的：探讨紫杉醇对兔血管内皮和平滑肌增生影响的差异及意义.方法：将兔血管平滑肌细胞接种于共培养体系上室、内皮细胞接种于下室建立体外内膜修复模型,观察紫杉醇对兔血管平滑肌和内皮细胞3H-TdR掺入、细胞计数和迁移率的影响,用直线回归法计算紫杉醇对平滑肌和内皮细胞增生迁移的半数有效抑制浓度IC50.结果：在1 nmol·L^-1～1 μmol·L^-1之间,紫杉醇呈浓度依赖地抑制平滑肌细胞^3H-TdR掺入、细胞计数和迁移（n=6, P＜0.01）.在10 nmol·L^-1～1 μmol·L^-1之间,紫杉醇呈浓度依赖地抑制内皮细胞3H-TdR掺入、细胞计数和迁移（n=6, P＜0.01）.1 nmol·L^-1紫杉醇对内皮细胞3H-TdR掺入和细胞计数有抑制倾向,但与对照组相比无统计学差异.而1 nmol·L^-1的紫杉醇却已显著抑制内皮细胞迁移（n=6, P＜0.01）.紫杉醇对兔血管平滑肌细胞增生、迁移抑制的IC50分别为 10.09±0.47、9.16±0.54 nmol·L^-1,对内皮细胞增生、迁移抑制的IC50分别为 19.05±0.35、5.37±0.51 nmol·L^-1.10 nmol·L^-1紫杉醇作用 20 min 在观察时间内能持续抑制融合内皮组平滑肌增生,而对数内皮组平滑肌增殖在10 d时明显高于对照组.结论：紫杉醇在抑制兔血管平滑肌细胞增生的同时也抑制内皮增生,紫杉醇干预后平滑肌细胞增生延迟与内皮细胞再生延迟密切相关. AIM： To investigate the effect of paclitaxel on the quantitative growth of rabbit＇s vascular smooth muscle cells （SMCs） and endothelial cells （ECs） and their relationship in vitro. METHODS： An ex vivo model of endothelium repair was developed in which rabbit＇s SMCs were inoculated in the upper chamber and rabbit＇s ECs in the lower chamber of a co-culture system. ^3 H-TdR incorporation and cell counting were used to determine the effect of paclitaxel on the quantitative proliferation of rabbit＇s vascular ECs and SMCs. The migration rate was analyzed to determine the effect of paclitaxel on the migration of rabbit＇s vascular ECs and SMCs. The IC50 of paclitaxel on ECs and SMCs was calculated. RESULTS： The 3 H-TdR incorporation, cell counting and migration of rabbit＇s vascular SMCs were inhibited by paclitaxel of 1 nmol·L^-1-1 μmol·L^-1 in a concentration-dependent manner （n=6, P〈0.01）. The ^3 H-TdR incorporation and cell counting of rabbit＇s vascular ECs were inhibited by paclitaxel of 10 nmol·L^-1-1 μmol·L^-1 and migration by paclitaxel of 1 nmol·L^-1-1 μmol·L^-1 in a concentration-dependent manner （n=6, P〈0.01）. The 3 H-TdR incorporation assay resulted in the IC50 of 10.09±0.47 nmol·L^-1 on SMCs and 19.06±0.35 nmol·L^-1 on ECs proliferation. The migration assay resulted in the IC50 of 9.16±0.54 nmol·L^-1 on SMCs and 5.37±0.51 nmol·L^-1 on ECs migration. Paclitaxel （10 nmol·L^-1, 20 min） inhibited SMCs growth of the confluent ECs group during the observed period. However, increased SMCs growth was observed in the proliferative ECs group 10 days after paclitaxel intervention. CONCLUSION： Paclitaxel inhibits not only SMCs but also ECs growth in rabbit＇s vascular. The delayed SMCs proliferation is closely related with the delayed ECs regeneration induced by paclitaxel.
作者 武晓静 葛均波 黄岚 周骐 邹云增
机构地区 第三军医大学新桥医院全军心血管内科中心 复旦大学中山医院上海市心血管病研究所
出处 《中国临床药理学与治疗学》 CAS CSCD 2006年第8期902-906,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 Supported by the National Natural Science Foundation of China(№30270568 №30400517)
关键词 紫杉醇 平滑肌细胞 内皮细胞 增生 共培养 Paclitaxel smooth muscle cell endothelial cell growth co-culture
分类号 R965 [医药卫生—药理学]
  • 相关文献

参考文献14

  • 1Lowe HC,Oesterle SN,Khachigian LM.Coronary in-stent restenosis:Current status and future strategies[J].J Am Coll Cardiol,2002,39:183-93
  • 2Weissman NJ,Koglin J,Cox DA,Hermiller J,O'Shaughnessy C,Mann JT,et al.Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation:a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial[J].J Am Coll Cardiol,2005,45:1201-15
  • 3Iakovou I,Schmidt T,Bonizzoni E,Ge L,Sangiorgi GM,Stankovic G,et al.Incidence,predictors,and outcome of thrombosis after successful implantation of drug-eluting stents[J].JAMA,2005,293:2126-30
  • 4Virmani R,Liistro F,Stankovic G,Di Mario C,Montorfano M,Farb A,et al.Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans[J].Circulation,2002,106:2649-51
  • 5Losordo DW,Isner JM,Diaz-Sandoval LJ.Endothelial recovery the next target in restenosis prevention[J].Circulation,2003,107:2635-7
  • 6Grobmyer SR,Kuo A,Orishimo M,Okada SS,Cines DB,Barnathan ES.Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells[J].J Biol Chem,1993,268:13291-300
  • 7Wei EH,Rao MR,Chen XY,Fan LM,Chen Q.Inhibitory effects of praeruptorin C on cattle aortic smooth muscle cell proliferation[J].Acta Pharmacol Sin,2002,23:129-32
  • 8Trochon V,Mabilat C,Bertrand P,Legrand Y,Smadja-Joffe F,Soria C,et al.Evidence of involvement of CD44 in endothelial cell proliferation,migration and angiogenesis in vitro[J].Int J Cancer,1996,66:664-8
  • 9Gorog P,Kovacs IB.Inhibition of vascular smooth muscle cell migration by intact endothelium is nitric oxide-mediated:interference by oxidised low density lipoproteins[J].J Vasc Res,1998,35:165-9
  • 10Herdeg C,Oberhoff M,Karsch KR.Antiproliferative stent coatings:Taxol and related compounds[J].Semin Interv Cardiol,1998,3:197-9

同被引文献11

  • 1Burstein H. The distinctive nature of HER2 positive breast cancers[J]. New EnglJ Med, 2006, 353 (16) :1652--1654.
  • 2Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle [J]. J Cell Biochem, 2004,93(2) :242 -250.
  • 3Jeha S,Luo XN,Beran M,et al. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells [J]. Cancer Res,2006,56(6) :1445--1450.
  • 4Zhang HZ,Wang Y,Gao P, et al. Silencing stathmin gene expression by survivin promoter driven siRNA vector to reverse malignant phenotype of tumor cells [J].Cancer Biol Ther, 2006,5(11): 1457--1641.
  • 5Milross CG, Mason KA, Hunter NR, et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel[J]. J Natl Cancer Inst, 1996,88 (18) :1308--1314.
  • 6Cassimers L. The oplS/stathmin family of microtubule destabilizers[J]. Curr Opin Cell Bio, 2002,14 (1):18 -24.
  • 7Gadea BB, Ruderman JV. Aurora B is required for mitotic chromatininduced phosphorylation of Op18/ Stathmin[J]. Proc Natl Acad Sci USA, 2006,103 (12) :449.
  • 8Tuschl T, Borkhardt A. Small interfering RNAs:a revolutionary tool for the analysis of gene function andgenetherapy[J]. MolInterv, 2002,2(3):158-- 167.
  • 9Hainsworth JD, Sosman JA, Spigel DR, et al. Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC) [J]. Pro Am Soc Clin Oncol, 2004,22:382.
  • 10徐兵河.复发转移乳腺癌的化学治疗[J].中国实用内科杂志,2007,27(24):1913-1916. 被引量：20

引证文献1

二级引证文献1

中国临床药理学与治疗学
2006年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部